Coultreon Biopharma Secures $125M Series A to Advance Novel SIK3 Inhibitor for Autoimmune Diseases
核心洞察
Coultreon Biopharma (搜索) raised $125 million in Series A funding led by Sofinnova Investments (搜索) and co-led by Forbion (搜索) and Novo Holdings (搜索) to advance its autoimmune disease pipeline.
The company's lead candidate COL-5671 (搜索) is a first-in-class oral SIK3 (搜索) inhibitor that targets multiple inflammatory pathways and is currently in Phase 1 trials.
Coultreon plans to initiate Phase 2 trials in psoriasis (搜索) and ulcerative colitis (搜索) with potential clinical proof-of-concept data expected in 2027.
Coultreon Biopharma (搜索), a Belgium-based biotechnology company, has successfully closed an oversubscribed $125 million Series A financing round to advance its lead immunology program targeting autoimmune diseases (搜索). The financing was led by Sofinnova Investments (搜索) and co-led by Forbion (搜索) and Novo Holdings (搜索), with participation from Galapagos, Regeneron Ventures (搜索), Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund and Finchley Health Ventures.
Addressing Unmet Medical Needs in Autoimmune Disease
Autoimmune diseases (搜索) represent a significant area of unmet medical need, with many patients cycling through therapies that fail to deliver durable control of inflammation or disease progression. Current treatments often involve injectable biologics that broadly suppress inflammation, leaving patients vulnerable to infections while frequently failing to provide sustained disease control.
Coultreon's approach is rooted in more than 15 years of research into salt-inducible kinases (SIKs), a family of proteins that regulate key inflammatory pathways. The company has identified SIK3 (搜索) as a central driver of pathogenic immune signaling, offering a differentiated and potentially more targeted approach to treating autoimmune disease.
COL-5671: A Novel SIK3 Inhibitor
The financing will support the clinical development of COL-5671 (搜索), a highly selective, oral once-daily SIK3 (搜索) inhibitor currently in Phase 1 studies. The drug was originally developed by Galapagos, with ownership fully transferred to Coultreon in April 2025 as part of Galapagos' pipeline trimming efforts.
COL-5671 (搜索) is designed to address core inflammatory pathways across multiple autoimmune diseases (搜索) through a novel mechanism of action. By targeting SIK3 (搜索), the therapy reduces transcription of key pro-inflammatory cytokines, including TNFα (搜索) and IL-23 (搜索), while increasing expression of the immunoregulatory cytokine IL-10. This differentiated mechanism has the potential to deliver broader and more durable disease control compared to existing therapies.
Clinical Development Timeline
Coultreon plans to advance COL-5671 (搜索) into Phase 2 clinical trials for psoriasis (搜索) and ulcerative colitis (搜索), with potential to demonstrate clinical proof-of-concept in 2027. The company believes the drug might be useful against multiple immune disorders, including Crohn's disease (搜索), psoriatic arthritis (搜索), and rheumatoid arthritis (搜索).
In preclinical and early clinical studies, COL-5671 (搜索) has demonstrated favorable pharmacokinetics with once-daily dosing, potent and sustained suppression of inflammatory cytokines, and a safety profile supported by extensive toxicology studies.
Leadership Perspectives
"This financing marks a major inflection point for our company," said Pierre Raboisson, CEO at Coultreon Biopharma (搜索). "With the support of this top-tier syndicate, we are well positioned to advance our SIK program, while unlocking the broader potential of our pipeline. I am extremely proud of what the team has achieved, and I look forward to advancing our novel first-in-class therapies to patients."
Max Klement, Partner, Venture Investments at Novo Holdings (搜索), who will join Coultreon's Board of Directors, commented: "We are very pleased to support Coultreon Biopharma (搜索) as it advances its differentiated approach to addressing significant unmet needs in autoimmune disease. Built on a strong scientific foundation originating from Galapagos, COL-5671 (搜索) has the potential to transform treatment paradigms by targeting multiple core inflammatory pathways in a single oral therapy."
Strategic Implications
Raboisson emphasized the fundamental nature of their approach, stating that "SIK3 (搜索) inhibition represents a fundamentally new approach to modulating immune pathways, and we look forward to moving into Phase 2 trials this year to begin generating meaningful clinical data that could reshape how these diseases are treated."
The investment reflects the growing interest in more precise and convenient approaches to treating autoimmune diseases (搜索), with drug developers increasingly seeking alternatives to current injectable biologics that can provide better disease control while reducing the risk of infections and other side effects associated with broad immunosuppression.